Nebivolol Stada

Nebivolol, the active ingredient in Nebivolol Stada, is a beta‑blocker presented as an oral tablet for oral use. It is employed to lower high blood pressure in adult patients and to improve cardiovascular outcomes. It works by selectively blocking β1‑adrenergic receptors while also promoting nitric‑oxide mediated vasodilation, which contributes to its blood‑pressure‑lowering effect.

GNH USA supplies Nebivolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality assurance and regulatory standards to ensure product integrity.

Nebivolol is a selective β1‑adrenergic blocker used in the management of cardiovascular conditions related to high blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Nebivolol may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: feeling of tiredness or reduced energy. - Nausea: upset stomach or urge to vomit. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: dangerously low blood pressure causing fainting. - Heart block: impaired electrical conduction in the heart. - Bronchospasm: tightening of airway muscles, especially in asthmatic patients. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzyme elevations.

When prescribing Nebivolol, clinicians should observe several precautionary measures to ensure patient safety.

- Blood pressure monitoring: check baseline and periodic readings to assess response. - Cardiac function assessment: evaluate for existing heart block or severe bradycardia before initiation. - Asthma/COPD caution: use carefully in patients with reactive airway disease due to potential bronchoconstriction. - Gradual discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Concomitant liver disease: dose may need adjustment in hepatic impairment. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Nebivolol can interact with other medicines, altering its effectiveness or increasing risk of adverse events.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increased plasma levels leading to excessive cardiac depression. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): may raise Nebivolol concentrations. - Clonidine: concurrent use can cause severe hypotension. - Insulin or oral hypoglycemics: enhanced glucose‑lowering effect, risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate blood‑pressure‑lowering effect. - NSAIDs: can blunt antihypertensive response. - Antidepressants (sertraline, venlafaxine): possible additive effects on heart rate. - Antihypertensives (ACE inhibitors, ARBs): monitor for excessive hypotension. - Antiarrhythmic agents (amiodarone): observe for conduction disturbances.